US FDA, AAMI Explore How To Consider Benefits, Risks In Postmarket
This article was originally published in Clinica
Executive Summary
The US FDA and industry efforts to clarify benefit-risk considerations for medical devices have moved into the postmarket space, with FDA draft guidance and a draft report from a working group led by the Association for the Advancement of Medical Instrumentation (AAMI), both issued on June 15.